HC Wainwright Boosts Aptose Biosciences (NASDAQ:APTO) Price Target to $6.00

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its price objective raised by research analysts at HC Wainwright from $2.00 to $6.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price indicates a potential upside of 80.18% from the stock’s current price.

Several other equities research analysts have also recently weighed in on APTO. StockNews.com started coverage on shares of Aptose Biosciences in a research report on Thursday. They set a “sell” rating for the company. Alliance Global Partners upgraded shares of Aptose Biosciences to a “strong-buy” rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Aptose Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $112.00.

Aptose Biosciences Stock Performance

APTO stock traded down $0.37 during trading on Friday, hitting $3.33. 27,110 shares of the company traded hands, compared to its average volume of 224,082. The company has a 50-day moving average of $4.63 and a 200-day moving average of $7.59. Aptose Biosciences has a 1 year low of $2.39 and a 1 year high of $51.61. The firm has a market capitalization of $7.13 million, a PE ratio of -1.12 and a beta of 1.14.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp increased its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the period. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.